Acuity's move in RNA-eye

The chances that the first RNAi-based treatment will enter the clinic in the near term rose last week after researchers at Acuity Pharmaceuticals Inc. announced that they had demonstrated efficacy of an siRNA compound in a primate model.

Scientists at the ophthalmic play tested the company's Cand5 siRNA-based inhibitor of vascular endothelial growth factor RNA translation in a primate model of age-related wet macular degeneration (wet AMD) using laser-induced neovascularization...